KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Free Cash Flow (2016 - 2025)

Resmed (RMD) has disclosed Free Cash Flow for 17 consecutive years, with $311.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 8.07% year-over-year to $311.2 million, compared with a TTM value of $1.8 billion through Dec 2025, up 28.73%, and an annual FY2025 reading of $1.7 billion, up 27.65% over the prior year.
  • Free Cash Flow was $311.2 million for Q4 2025 at Resmed, down from $414.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $557.9 million in Q1 2025 and bottomed at -$93.0 million in Q3 2021.
  • Average Free Cash Flow over 5 years is $242.4 million, with a median of $251.6 million recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 171.26% in 2021, then surged 1541.98% in 2023.
  • Year by year, Free Cash Flow stood at $189.5 million in 2021, then crashed by 46.54% to $101.3 million in 2022, then surged by 146.31% to $249.5 million in 2023, then grew by 15.43% to $288.0 million in 2024, then rose by 8.07% to $311.2 million in 2025.
  • Business Quant data shows Free Cash Flow for RMD at $311.2 million in Q4 2025, $414.4 million in Q3 2025, and $508.2 million in Q2 2025.